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Abstract: Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental 
disorder in childhood, which is generally treated with stimulant and non-stimulant medications. 
However, 10–30% of patients in clinical setting do not present with adequate response to initial 
stimulant treatment. Thereby, clonidine may be considered for those patients who have failed to 
respond to psychostimulant/atomoxetine monotherapy or as an augmentation for inadequate 
response/comorbidity. This observational study evaluated its effectiveness as a single drug in ADHD 
cases unresponsive to previous treatment trials. Seventeen ADHD cases that were non-responders to 
stimulant, non-stimulant and combination therapy for the primary symptoms of ADHD were included in 
the study. Four cases dropped out before follow up, leaving thirteen cases who were administered 
immediate release clonidine treatment alone with a mean dose of 0.2 ± 0.05 mg/day at baseline. The 
trial lasted for 12 weeks, and treatment outcomes were evaluated by the Turgay DSM-IV Based 
Child and Adolescent Behavior Disorders Screening and Rating Scale (T-DSM-IV-S) and the Clinical 
Global Impressions-Severity (CGI-S) and Improvement (CGI-I) scales. Mean age of the sample was 
12.5 years (SD = 3.0) and eleven of the subjects had another comorbid psychopathology. Only two 
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cases were evaluated as “very much improved”, while another patient was judged to be “minimally 
improved” after 12 weeks of clonidine treatment. Attrition during follow-up was associated with 
higher median scores on the hyperactivity and impulsivity subscales (Mann-Whitney U test, p = 
0.02). According to the T-DSM-IV-S, CGI-S, and CGI-I scales, clonidine treatment by itself had 
minimal benefits in this sample of treatment of refractory cases with ADHD evaluated at the study 
center. Clonidine is not available in Turkey pharmaceutical marketing system and patients’ access to 
drug is limited. Our results provide first data regarding the use of clonidine in Turkish ADHD 
patients. 
Keywords: Alpha-2 adrenergic receptor agonist; Attention-Deficit/Hyperactivity Disorder; 
Clonidine 
 
Abbreviations: T-AD: Attention-deficit subscale; T-HIP: Hyperactivity/impulsivity subscale; ODD: 
Oppositional defiant disorder subscale; CD: Conduct disorder subscale; CGI-S: Clinical Global 
Impressions-Severity scale 
1. Introduction 
ADHD is a common childhood neurodevelopmental disorder that affects around 5.2% of 
children worldwide [1]. The disorder is marked by inattention, hyperactivity, and/or impulsivity that 
can seriously impair emotional, educational, and social development in children. Male children are 
twice as likely to be diagnosed as similarly aged females. However, this may be due to males 
expressing more hyperactive symptoms, while females demonstrate inattentiveness more often, 
which may be harder to detect [2]. ADHD is also often comorbid with oppositional defiant disorder, 
tic disorder, conduct disorder, anxiety disorder, and autism. It often requires multi-modal treatments, 
including both behavioral and pharmacological treatments such as stimulants and non-stimulant 
medications [2,3]. Among those medications, psychostimulants are the most widely prescribed 
pharmacologic treatment for ADHD around the world [4,5]. While psychostimulants are prescribed 
as first-line treatment for a significant number of patients, ADHD symptoms can remain uncontrolled 
by psychostimulants in 10% to 30% of patients [4–7]. Furthermore, psychostimulant effectiveness 
may be restricted by side effects and tolerability issues, such as weight loss and sleep problems in 
children [8]. For those patients, the availability of alpha-2 adrenergic receptor agonists, such as 
clonidine, for the treatment of ADHD increases the prospect of better ADHD control and comorbid 
disorders such as tic disorders, sleep disorders and conduct disorders [9–11]. 
Previous studies on the efficacy of alpha-2 adrenergic receptor agonists were conducted 
mostly in the US and clinical experience with those agents in Turkey has been very limited. 
Therefore, the goal of the present study was to evaluate the efficacy of clonidine as a single agent 
in methylphenidate/atomoxetine-resistant ADHD cases diagnosed at a single tertiary treatment 
center in Turkey. 
2. Material and methods 
2.1. Sample 
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This study was conducted between January 2012 and August 2015 at the Malatya State 
Hospital’s Child and Adolescent Psychiatry Clinic. Inclusion criteria were being diagnosed with 
ADHD according to Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision 
(DSM-IV-TR) criteria, having received at least one prior stimulant and non-stimulant prescription 
alone or together at an adequate dose (1.2 mg/kg/day for stimulants, 1.4 mg/kg/day for atomoxetine) 
for an adequate duration (>three months) but without response (<20.0% change in parent and teacher 
reports) and providing informed consent for study (for parents) and written assent for children. Apart 
from the presence of psychosis and chronic medical disorders requiring treatment (such as asthma, 
epilepsy and celiac disease) no criteria were set for exclusion. Within the study period 357 patients 
with ADHD were evaluated at the study center and pharmacotherapy was provided for 67.2% 
(n = 240). Forty-one of the patients (16.6%) were classified as treatment resistant and approached for 
inclusion. Fifteen of the patients were excluded due to chronic medical disorders (Seven with asthma, 
four with epilepsy and one with abnormalities in the electroencephalogram, three with celiac disease) 
while parents of the remaining nine patients refused participation. Seventeen patients were judged to 
be eligible at baseline and cardiologic evaluations were planned prior to clonidine treatment. Four of 
the patients were lost to follow-up at this stage leaving thirteen patients. 
0.1 mg immediate release (IR) clonidine tablets were prescribed to these patients which were 
brought from abroad by the Ministry of Health via direct international import route. Clonidine was 
planned to be given at a dose of 0.05 mg daily at the beginning and then gradually increased to two 
divided doses with a maximum dose being 0.4 mg. The duration of treatment was 12 weeks. The 
cases were evaluated at baseline, and at the end of the 12th week of treatment. Ethical approval was 
obtained from Turkish Ministry of Health and Malatya Training and Research Hospital for the 
present study (Ethical Committee approval number: 59728196/640/12073). 
2.2. Instruments 
Turgay DSM-IV-Based Child and Adolescent Behavior Disorders Screening and Rating Scale 
(T-DSM-IV-S): This scale was completed by the parents to determine the severity of ADHD in 
children. The T-DSM-IV-S was developed to assess symptoms of disruptive behavior disorders 
according to DSM-IV criteria. It includes 9 items related to attention-deficit, 9 items related to 
hyperactivity, 3 items related to impulsivity, 8 items related to oppositional defiant disorder (ODD), 
and 15 items related to conduct disorder (CD). All questions were answered on a Likert scale with 4 
categories according to severity (i.e., 0 = absent, 1 = low, 2 = high, 3 = very high). The scale was 
found to be reliable and valid in previous studies [12]. In the present study, the internal consistency 
of the scale was found to be quite high (Cronbach alpha coefficient = 0.899). 
Clinical Global Impressions Scale: This scale was developed for use in clinical studies. It has 3 
domains evaluating the severity of disorder, magnitude of improvement with treatment, and adverse 
effects. Only the severity and improvement scales were used in the present study. 
For severity (CGI-S), the subject with psychopathology was scored by a clinician on a scale 
from 1 to 7 according to the severity of disorder at the time of observation (1 = normal, not at all ill, 
2 = borderline mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = extremely 
ill). Improvement (CGI-I) was also scored by the clinician on a scale from 1–7 according to the 
change in health status from the onset of the study (1 = very much improved, 2 = much improved, 
3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse). 
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2.3. Statistical analyses 
Statistical analyses were performed using the SPSS v.22.0 statistical package. Wilcoxon tests 
were used to compare before- and after-treatment scores, and the Mann-Whitney U test was used to 
compare two independent groups, because the data were not normally distributed. Categorical 
variables were analyzed with the Fisher-Freeman-Halton test. Statistical significance level was 
considered as p < 0.05. 
3. Results 
Seventeen children and adolescents (fourteen boys) were included. Most of the children (n = 12) 
were in primary school, and the remainder was in high school. Mean and median age of the cases 
were 12.5 (SD = 3.0) and 12.0 (Inter quartile range, IQR = 5.0) respectively. Most of the cases were 
born at term and without complications during labor (n = 11). In eleven cases, there was a comorbid 
psychiatric disorder and in one case there was one medical comorbid disorder. Comorbid diagnoses 
of the cases are summarized in Table 1. 
Table 1. The comorbid diagnoses of cases diagnosed with ADHD given open-ended, 
prospective clonidine treatment, according to sex. 
Comorbid diagnosis (n, %) Boys (n = 9) Girls (n = 2) Overall (n = 11) 
Tic disorders 4 (44.4%) 1 (50.0%) 5 (45.5%) 
Conduct disorder 3 (33.3%) 0 (0.0%) 3 (27.3%) 
Any Anxiety disorder 0 (0.0) 1 (50.0%) 1 (9.1%) 
Obsessive Compulsive Disorder 1 (11.1%) 0 (0.0%) 1 (9.1%) 
Mental Retardation* 1 (11.1%) 0 (0.0%) 1 (9.1%) 
* IQ < 70 as evaluated with the Turkish version of WISC-R (Savasir I, Sahin N. Manual for the Wechsler 
Intelligence Scale for Children- Revised (WISC-R). Turkish Psychologists’ Association Press, Ankara 1995). 
In most cases, both parents had a high school or more advanced education (n = 12). The fathers 
were mostly civil servants (n = 7). Five mothers and two fathers had psychiatric disorders and were 
undergoing treatment. Three were relatives rather than biological parents. Cases were evaluated 
using T-DSM-IV-S completed by the parents before treatment and at the 12th week of treatment, and 
the CGI-S and CGI-I were completed by the clinician. The scores of cases before and after treatment 
are outlined in Table 2. Median and mean doses of clonidine at baseline and at the 12th week of 
treatment respectively were 0.5 and 0.06 mg/day (SD = 0.02 mg/day) and 0.2 and 0.2 mg/day 
(SD = 0.06 mg/day). When CGI-S and T-DSM-IV-S test scores of the cases before and after 
treatment were evaluated with the Wilcoxon test, no statistically significant difference was found. 
When the CGI-I scale was evaluated, only three patients were found to have benefited from clonidine 
(Table 3). Importantly, all these patients were male. One had obsessive-compulsive disorder as a 
comorbid disorder with ADHD. Another with a conduct disorder benefited greatly from treatment 
and a patient with a tic disorder showed improvement. Four cases dropped out of the follow-up and 
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treatment process during the study; their median scores from the hyperactivity and impulsivity 
subscale were found to be significantly higher than those of the rest of the cases (p = 0.023) (Table 4). 
Eight cases reported side effects with clonidine treatment. Side effects by order of frequency were as 
follows: Sedation (n = 4), nausea/vomiting (n = 2), vertigo and increased hyperactivity (for both; 
n = 1). Chi-square test found no significant relation between the presence of side effects and 
dropping out from treatment (p = 0.893). 
Table 2. Comparison of psychometric measurements in ADHD cases, before and after 
treatment with clonidine. 
Scale 
Prior to treatment  After treatment  
p* 
Median (IQR)  Median (IQR)  
T-AD 0 (0–3)  0 (0–4)  0.27 
T-HI 7 (3–9)  8 (2–9)  0.59 
T-ODD 8 (4–8)  8 (7–8)  0.19 
T-CD 15 (14–15)  15 (14–15)  0.32 
T-overall 29 (23–33)  31 (25–36)  0.44 
CGI-S 5 (4–6)  4 (4–5)  0.02 
* Wilcoxon test. 
Table 3. CGI-I values at the 12th week of treatment. 
 Score n (%) 
CGI-I 1 = very much improved 
 
 
 
 
1 (7.7) 
2 = much improved 1 (7.7) 
3 = Minimally improved 1 (7.7) 
4 = no change 8 (47.1) 
5 = Minimally worse 2 (11.8) 
CGI-I: Clinical Global Impressions Scale, Improvement. 
Table 4. Comparison of psychometric measurements in ADHD cases who dropped out 
of clonidine treatment with those who continued treatment. 
Scale 
Continued treatment  Dropped out from treatment  
p* 
Median (IQR)  Median (IQR)  
T-AD 0 (0–3)  1 (0–4)  0.55 
T-HIP 7 (3–9)  1 (0–2)  0.02 
T-ODD 8 (4–8)  6 (3–8)  0.48 
T-CD 15 (14–15)  15 (14–15)  0.96 
T-overall 29 (23–33)  24 (17–26)  0.13 
CGI-S 5 (4–6)  -  - 
* Mann-Whitney U test. 
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4. Discussion 
As far as we are aware, this is the first open-label study of clonidine on children with treatment 
refractory ADHD reported from Turkey. Even with a broad range of definitions for improvement, 
only three of the sample benefited from treatment according to the clinician’s judgment, while 
parental reports showed no benefit. Adverse effects were also frequent. Previous studies showed that 
although stimulants are the primary therapy for patients with ADHD, adverse events, 
comorbidities, contraindications, partial responses, and lack of response might restrict their use 
in some patients [9,13–15]. Alpha-2 agonists, IR clonidine and guanfacine, which are used for 
blood pressure control, were used off-label as second-line agents for patients who failed to respond 
to psychostimulants or as adjunctive therapy for patients with suboptimal results with a 
psychostimulant alone [6,16,17]. Clonidine has also been shown to be beneficial for CD, ODD, tic 
disorder, sleep problems, mental retardation and anxiety disorder, which are comorbid with 
ADHD [3,9,18–21]. A systematic review and meta-analysis of 12 placebo-controlled trials of alpha-2 
agonists as monotherapy or augmentation was recently carried out to evaluate the safety and efficacy 
of alpha-2 agonists in ADHD in children and they were proved to be superior to placebo as 
monotherapy and to a lesser degree as co-treatment [22]. Another meta-analysis of 11 small 
double-blind and open-label studies reviewing the effect of immediate-release clonidine on 
symptoms of ADHD alone or with comorbidities determined a moderate overall effect size [1]. But 
when comparing the alpha-2 agonists to psychostimulants as monotherapy for ADHD, the alpha-2 
agonists did not perform nearly as well. Evaluations have demonstrated that clonidine and 
guanfacine are around 40% to 75% as effective as psychostimulants in managing the primary 
symptoms of ADHD [23,24]. 
In the present study, cases were evaluated before and at the 12th week of the study with 
T-DSM-IV-S completed by parents and the CGI-S and CGI-I scales completed by a clinician. No 
significant differences were seen in the CGI-S or T-DSM-IV-S test results before and after treatment. 
The results of this study showed that clonidine is not effective as a single agent in children and 
adolescents with ADHD who had at least one stimulant and non-stimulant prescription alone or 
together before and did not respond these medications for primary symptoms of ADHD. All cases in 
the present study were difficult ones who had undergone stimulant and atomoxetine treatment alone 
or in combination in our clinic for a mean of two years at adequate doses and duration, but without 
improvement in ADHD symptoms. This duration may be due to the features of clinical practice in 
our country and may have affected our results. According to the prevalent practice of child and 
adolescent psychiatrists in Turkey, stimulants are frequently the first step in treatment of ADHD 
which is continued for three months with upward titration of dose. An unsuccessful trial of one type 
of stimulant leads to a trial with another form (i.e. long acting) and atomoxetine is usually reserved 
for the third step. Children and their families are usually not brought for treatment during the 
summer which forces clinicians to repeat the steps for the successive school semester and attempting 
to combine atomoxetine and stimulants as a last resort. 
Also, most patients had other comorbid disorders. As shown in previous studies, the 
heterogeneous nature of ADHD symptoms, comorbidities, and pharmacogenetics of patients may 
have led to poor outcomes for all medications [25–27]. In addition, previous studies have reported 
various reasons for non-adherence to medication in ADHD such as male gender, severe ADHD 
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symptoms, oppositional-defiant symptoms, and parental opposition to use of medication as well as 
side effects [28,29]. 
In the present study, four cases dropped out from treatment during the study. Three out of these 
four cases were male, and their files reported that they were reluctant to engage in more treatment 
and felt hopeless, since they failed to benefit from their previous treatments. These four cases had 
also significantly higher median scores on the hyperactivity and impulsivity scale (p = 0.023) than 
the rest of the cases at the beginning of the study. In addition, eight cases reported side effects from 
clonidine treatment. Side effects by order of frequency were as follows: Sedation (n = 4), 
nausea/vomiting (n = 2), vertigo and increased hyperactivity (for both; n = 1). No significant relation 
was found between the presence of side effects and the rate of dropping out from the study (p = 0.893) 
like other studies [10]. In other related studies, the IR formulation of clonidine had adverse effects 
including somnolence, sedation, drowsiness, and irritability. IR clonidine has a relatively short 
half-life, and the need for frequent dosing may have led to increased side effects [10,14–16,20,23]. 
Unfortunately, clonidine is not available in Turkey. In these resistant cases, IR clonidine could 
be imported with the approval of the Ministry of Health. We could not get Ministry of Health 
approval to import the drug for patients other than the 17 patients mentioned in the study (i.e. on 
children with less severe symptoms and greater response to previous treatments). Hence, we could 
use it only on these patients between these years. This was an important limitation of the study. 
Another limitation was that this was an uncontrolled study with a short duration of follow-up. A 
longer follow-up may have provided greater information on long term effects of clonidine treatment. 
Further limitations include lack of teacher observations and objective evaluations of treatment effects 
(e.g. with neuropsychological tests). Additional treatment studies with larger populations are 
warranted in Turkey about the effects of clonidine, especially since the US Food and Drug 
Administration approved the extended release form for children and adolescents with ADHD. 
Therefore, we believed that this drug should be more easily available for Turkish patients. Further 
studies are required to compare alpha-2 agonists head-to-head with psychostimulants and with atomoxetine. 
5. Conclusions and clinical significance 
As far as we are aware, this is the first longitudinal, naturalistic, open-label study of clonidine 
on children with treatment refractory ADHD reported from Turkey. According to the T-DSM-IV-S, 
CGI-S, and CGI-I scales, clonidine treatment by itself had minimal benefits in this sample of 
treatment of refractory cases with ADHD evaluated at the study center. Previous studies on the 
efficacy of alpha-2 adrenergic receptor agonists were conducted mostly in the US, and clinical 
experience with those agents in Turkey has been very limited and our results should be replicated 
with larger studies from multiple centers in our country. 
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